Haemonetics (HAE) Set to Announce Earnings on Thursday

Haemonetics (NYSE:HAE) is scheduled to announce its earnings results before the market opens on Thursday, May 9th. Analysts expect the company to announce earnings of $0.88 per share for the quarter. Haemonetics has set its FY 2024 guidance at 3.900-4.000 EPS and its FY24 guidance at $3.90-4.00 EPS.Individual that wish to register for the company’s earnings conference call can do so using this link.

Haemonetics (NYSE:HAE) last issued its quarterly earnings results on Thursday, February 8th. The medical instruments supplier reported $1.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.94 by $0.10. Haemonetics had a return on equity of 22.37% and a net margin of 9.97%. The business had revenue of $336.20 million during the quarter, compared to analysts’ expectations of $320.84 million. The firm’s revenue for the quarter was up 10.1% compared to the same quarter last year. During the same period in the previous year, the company posted $0.85 earnings per share. On average, analysts expect Haemonetics to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Haemonetics Price Performance

Shares of NYSE HAE opened at $95.15 on Wednesday. The stock has a market capitalization of $4.83 billion, a PE ratio of 38.68, a P/E/G ratio of 2.23 and a beta of 0.34. Haemonetics has a fifty-two week low of $70.74 and a fifty-two week high of $97.13. The company has a debt-to-equity ratio of 0.91, a current ratio of 2.92 and a quick ratio of 1.76. The business has a fifty day moving average price of $83.22 and a two-hundred day moving average price of $82.74.

Wall Street Analyst Weigh In

HAE has been the subject of several recent analyst reports. Barrington Research reaffirmed an “outperform” rating and set a $105.00 price objective on shares of Haemonetics in a research report on Friday, April 12th. StockNews.com downgraded shares of Haemonetics from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Finally, TheStreet cut shares of Haemonetics from a “b-” rating to a “c+” rating in a research note on Thursday, February 29th.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.